Gritstone secures CEPI funding to test Covid vaccine; first focus is South Africa
August 23, 2021
Excerpt from the Press Release:
Gritstone bio is developing Covid-19 vaccines that use self-amplifying messenger RNA, which is intended to further boost the immune response compared to mRNA alone. The company also says its vaccine candidates may be able to protect against variants of the novel coronavirus.
As coronavirus variants continue to fuel the ongoing pandemic, Gritstone bio is pressing ahead with its second-generation Covid-19 vaccine, now with financing from the Coalition for Epidemic Preparedness Innovations (CEPI) to support additional clinical trials.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?